Investors Are Undervaluing Jacobson Pharma Corporation Limited (HKG:2633) By 35.82%

Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Dane Simmons

Wed, Feb 13, 2019, 5:03 PM

How far off is Jacobson Pharma Corporation Limited (HKG:2633) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. I will be using the Discounted Cash Flows (DCF) model. Don’t get put off by the jargon, the math behind it is actually quite straightforward. If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model. If you are reading this and its not February 2019 then I highly recommend you check out the latest calculation for Jacobson Pharma by following the link below.

View our latest analysis for Jacobson Pharma

Crunching the numbers

I use what is known as a 2-stage model, which simply means we have two different periods of varying growth rates for the company’s cash flows. Generally the first stage is higher growth, and the second stage is a more stable growth phase. In the first stage we need to estimate the cash flows to the business over the next five years. For this I used the consensus of the analysts covering the stock, as you can see below. I then discount this to its value today and sum up the total to get the present value of these cash flows.

5-year cash flow forecast

	2019	2020	2021	2022	2023
Levered FCF (HK$, Millions)	HK$316.00	HK$230.00	HK$356.00	HK$406.16	HK$463.38
Source	Analyst x1	Analyst x1	Analyst x1	Est @ 14.09%	Est @ 14.09%
Present Value Discounted @ 9.98%	HK$287.32	HK$190.15	HK$267.61	HK$277.61	HK$287.98

Present Value of 5-year Cash Flow (PVCF)= HK$1.3b

We now need to calculate the Terminal Value, which accounts for all the future cash flows after the five years. For a number of reasons a very conservative growth rate is used that cannot exceed that of the GDP. In this case I have used the 10-year government bond rate (2%). In the same way as with the 5-year ‘growth’ period, we discount this to today’s value at a cost of equity of 10%.

Terminal Value (TV) = FCF₂₀₂₃ × (1 + g) ÷ (r – g) = HK$463m × (1 + 2%) ÷ (10% – 2%) = HK$5.9b

Present Value of Terminal Value (PVTV) = TV / (1 + r)⁵ = HK$5.9b ÷ ( 1 + 10%)⁵ = HK$3.7b

The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is HK$5.0b. The last step is to then divide the equity value by the number of shares outstanding. If the stock is an depositary receipt (represents a specified number of shares in a foreign corporation) then we use the equivalent number. This results in an intrinsic value of HK$2.48. Compared to the current share price of HK$1.59, the stock is quite good value at a 36% discount to what it is available for right now.

SEHK:2633 Intrinsic Value Export February 14th 19

The assumptions

I’d like to point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don’t agree with my result, have a go at the calculation yourself and play with the assumptions. Because we are looking at Jacobson Pharma as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 10%, which is based on a levered beta of 0.998. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, DCF calculation shouldn’t be the only metric you look at when researching a company. What is the reason for the share price to differ from the intrinsic value? For 2633, there are three key aspects you should look at:

Financial Health: Does 2633 have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
Future Earnings: How does 2633’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of 2633? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St does a DCF calculation for every HK stock every 6 hours, so if you want to find the intrinsic value of any other stock just search here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.

Terms and Privacy Policy

Your Privacy Choices

Utah Privacy Notice

More Info